Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY

HERRINGTON W., (2024), Clinical and Experimental Nephrology

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), Lancet Child and Adolescent Health

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

PETO L. et al, (2023), Nature Communications

Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial

HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology

Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial

Judge P. et al, (2023), Lancet Diabetes and Endocrinology

Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.

Wijesurendra RS. et al, (2023), Eur Heart J

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Accelerating clinical trials: time to turn words into action

LANDRAY M. et al, (2023)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Sacubitril/valsartan in Peritoneal Dialysis – Lessons from a Pharmacokinetic Study

Judge P., (2023)

Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery

Wijesurendra RS. et al, (2023)

Randomised controlled trials for mpox in endemic countries.

Rojek A. et al, (2023), Lancet Infect Dis

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: the DECODE-CKD trial.

Bartholdy KV. et al, (2022), Kidney360

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study

HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Determining the Relationship between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights from Genetic Epidemiology

HERRINGTON W. et al, (2022), Hypertension

The Health and Care Act 2022: key challenges and priority actions for embedding research in the NHS

HAYNES R., (2022), The Lancet

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?